Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Pharmacokinetics, metabolism and elimination of itanoxone in humans

  • 15 Accesses

  • 2 Citations

Summary

The pharmacokinetics, metabolism and elimination of Itanoxone was studied after a single oral administration of the carbon-14-1 abelled drug (500 mg) in four male volunteers. The drug was absorbed fairly rapidly with a mean peak plasma level of 10.3±1.3 μg/ml between 3 and 4 hours after dosing. The pharmacokinetics can be described by a two-compartment open model with the central compartment consisting of the extracellular fluid. The mean elimination half-life was 19.4±8.5 hours. Two metabolites as well as unchanged Itanoxone were detected in plasma.

Approximately 37% of the radioactivity was excreted over a five-day period in the urine and 50% in the faeces. There were only traces of free metabolites in the urine as the rest of the radioactive metabolites were associated with glucuronide conjugates. These conjugates consisted of Itanoxone and up to six metabolites. Five of these metabolites have been tentatively identified by comparison of their chromatographic properties by TLC and HPLC with a number of reference compounds.

After repeated administration of Itanoxone (250 mg b.i.d.) the maximum level at steady state was about 7 μg/ml and the minimum level, 0.6 μg/ml. The mean area under the plasma level time curve was 35% higher than in the single dose study after correction for dose.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bizzi A., Tacconi M.T., Veneroni E. and Cini M. (1978): “7th International Congress of Pharmacology”, Paris, France.

  2. 2.

    Lubetzki J. and Mose A. (1979): “International Conference on Atherosclerosis”, Milan, Italy, Nov. 1979.

  3. 3.

    Delhon A., Tarayre J.P., Lauressergues H., Casadio, S. (1978): Itanoxone — A new hypolipidemic, hypo-uricemic agent with moderate antiflammatory properties. In: Carlson L.A., Paoletti R., Sirtori C.R., Weber G. (eds). International Conference on Atherosclerosis. Raven Press, New York.

  4. 4.

    Mazoyer F. (to P. Fabre S.A.), U.S. pat. 105,420, 1979.

  5. 5.

    Cousse H., Bonnaud B., Pichat L., Aubert F. (1976): Préparation de l’acide biphényl-4-oxo-4-méthylène-2 butyrique14C. J. Label. Compounds4, 49–57.

  6. 6.

    Niazi S. (1979): Multicompartment pharmacokinetic analysis and simulations using a programmable calculator. Int. J. Biomed. Comput.10, 245–255.

  7. 7.

    Urien S., Albengres E., Zini R., d’Athis P., Tillement J.P. (1980): Presented at the VII International Symposium on Drugs Affecting Lipid Metabolism, Milan, May 1980.

  8. 8.

    Smith R.L. (1969): The metabolism of drugs. In: Clarke E.G.C. (ed) Isolation and Identification of Drugs. The Pharmaceutical Press, London.

  9. 9.

    West H.D., Lawson J.R., Miller I.H., Mathura G.R. (1956): The fate of diphenyl in the rat. Arch. Biochem. Biophys.60, 14–20.

Download references

Author information

Correspondence to F. E. H. Crawley.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Crawley, F.E.H., Hyacinthe, R., Poitou, P. et al. Pharmacokinetics, metabolism and elimination of itanoxone in humans. European Journal of Drug Metabolism and Pharmacokinetics 8, 287–296 (1983). https://doi.org/10.1007/BF03188759

Download citation

Key words

  • Itanoxone
  • pharmacokinetics
  • metabolism
  • single
  • repeated administration